Chimerix Inc. (NASDAQ:CMRX)’s share price was down 1.2% on Friday . The company traded as low as $3.92 and last traded at $3.98, with a volume of 219,712 shares traded. The stock had previously closed at $4.03.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a report on Wednesday, May 11th. FBR & Co reissued a “hold” rating on shares of Chimerix in a report on Tuesday, May 10th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $16.98.

The stock’s market capitalization is $184.39 million. The stock has a 50-day moving average of $4.27 and a 200 day moving average of $6.61.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.66) by $0.09. The firm earned $1.20 million during the quarter, compared to analysts’ expectations of $2.79 million. On average, equities analysts anticipate that Chimerix Inc. will post ($2.06) EPS for the current year.

In related news, Director Ernest Mario purchased 50,000 shares of the business’s stock in a transaction on Friday, June 24th. The shares were bought at an average price of $3.70 per share, for a total transaction of $185,000.00. Following the acquisition, the director now directly owns 381,440 shares in the company, valued at $1,411,328. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO M Michelle Berrey purchased 13,188 shares of the business’s stock in a transaction on Friday, June 24th. The shares were bought at an average price of $3.69 per share, for a total transaction of $48,663.72. Following the acquisition, the chief executive officer now owns 258,821 shares in the company, valued at $955,049.49. The disclosure for this purchase can be found here.

A number of large investors recently modified their holdings of the company. Jennison Associates LLC increased its stake in shares of Chimerix by 67.9% in the fourth quarter. Jennison Associates LLC now owns 1,273,779 shares of the biopharmaceutical company’s stock valued at $11,400,000 after buying an additional 515,029 shares during the period. Numeric Investors LLC bought a new stake in shares of Chimerix during the fourth quarter valued at $2,076,000. Trexquant Investment LP increased its stake in shares of Chimerix by 453.5% in the fourth quarter. Trexquant Investment LP now owns 131,184 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 107,484 shares during the period. Finally, Morgan Stanley increased its stake in shares of Chimerix by 96.7% in the fourth quarter. Morgan Stanley now owns 187,163 shares of the biopharmaceutical company’s stock valued at $1,674,000 after buying an additional 92,005 shares during the period.

Chimerix, Inc a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.